Evidence map›Paper›PMID 22438952›Full record

ArticlePloS one2012

Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization.

Leah A Owen, Hironori Uehara, Judd Cahoon, Wei Huang, Jacquelyn Simonis, Balamurali K Ambati

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. VEGF-R1 as a Potential Molecular Target for Anticancer Therapy.Doklady. Biochemistry and biophysics · 2018
    Article
  11. Article
  12. Article
  13. Targeted Delivery of FLT-Morpholino Using Cyclic RGD Peptide.Translational vision science & technology · 2017
    Article
  14. Review
  15. Review
  16. AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Leah A OwenDepartment Of Ophthalmology, Moran Eye Center, University of Utah, Salt Lake City, Utah, United States of America.
Hironori Uehara
Judd Cahoon
Wei Huang
Jacquelyn Simonis
Balamurali K Ambati
University of Utah · USUniversity of Kentucky · US

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI PAUL STEVEN BERNSTEIN · 2005 to 2026
$14.6M
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular DemarcationsR01EY017950 · NEI · UNIVERSITY OF UTAH · PI AMBATI, BALAMURALI K · 2008 to 2021
$5.2M
Interdisciplinary Training Program in MetabolismT32DK091317 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI SCOTT A SUMMERS · 2011 to 2026
$4.8M
NEI NIH HHS 5R01EY017950NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY017950NIDDK NIH HHS T32 DK091317
6 · The paper itself

Abstract

backgroundAngiogenesis is a key process in several ocular disorders and cancers. Soluble Flt-1 is an alternatively spliced form of the Flt-1 gene that retains the ligand-binding domain, but lacks the membrane-spanning and intracellular kinase domains of the full-length membrane bound Flt-1 (mbFlt-1) protein. Thus, sFlt-1 is an endogenous inhibitor of VEGF-A mediated angiogenesis. Synthetic mopholino oligomers directed against splice site targets can modulate splice variant expression. We hypothesize that morpholino-induced upregulation of sFlt-1 will suppress angiogenesis in clinically relevant models of macular degeneration and breast cancer. METHODS AND

findingsIn vivo morpholino constructs were designed to target murine exon/intron 13 junction of the Flt-1 transcript denoted VEGFR1_MOe13; standard nonspecific morpholino was used as control. After nucleofection of endothelial and breast adenocarcinoma cell lines, total RNA was extracted and real-time RT-PCR performed for sFlt-1 and mbFlt-1. Intravitreal injections of VEGFR1_MOe13 or control were done in a model of laser-induced choroidal neovascularization and intratumoral injections were performed in MBA-MD-231 xenografts in nude mice. VEGFR1_MOe13 elevated sFlt-1 mRNA expression and suppressed mbFlt-1 mRNA expression in vitro in multiple cellular backgrounds (p<0.001). VEGFR1_MOe13 also elevated sFlt/mbFlt-1 ratio in vivo after laser choroidal injury 5.5 fold (p<0.001) and suppressed laser-induced CNV by 50% (p = 0.0179). This latter effect was reversed by RNAi of sFlt-1, confirming specificity of morpholino activity through up-regulation of sFlt-1. In the xenograft model, VEGFR1_MOe13 regressed tumor volume by 88.9%, increased sFlt-1 mRNA expression, and reduced vascular density by 50% relative to control morpholino treatment (p<0.05).

conclusionsMorpholino oligomers targeting the VEGFR1 mRNA exon/intron 13 junction promote production of soluble FLT-1 over membrane bound FLT-1, resulting in suppression of lesional volume in laser induced CNV and breast adenocarcinoma. Thus, morpholino manipulation of alternative splicing offers translational potential for therapy of angiogenic disorders.

Indexed as

Alternative SplicingAnimalsBase SequenceBreast NeoplasmsCell Line, TumorChoroidal NeovascularizationFemaleGene Knockdown TechniquesHumansMiceMice, NudeMorpholinosNeovascularization, PathologicRNA, Small InterferingSolubilityTransplantation, HeterologousFLT1 protein, humanFlt1 protein, mouseMorpholinosRNA, Small InterferingVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID22438952
PMCPMC3305322
OpenAlexW4239723432

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.